Pascal Biosciences
shutterstock_309940142 (1).jpg

181128

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic and business development. These include Kevin M. Egan, MBA, Vice President Business Development, Thomas Deckwerth, PhD, Vice President Therapeutic Development, and Larry W. Tjoelker, PhD, Vice President Research.

“We are pleased to have Kevin, Tom, and Larry as members of the senior leadership team at Pascal. Their extensive experience is invaluable as we advance our leading cannabinoid-based programs and explore strategic opportunities,” said Dr. Patrick Gray, CEO of Pascal. “This great team has been responsible for the discovery and development of numerous drugs, both through clinical development and partnering.”

Mr. Egan brings over 30 years of experience in the biotechnology industry with a proven track record of negotiating partnering, licensing, and outsourcing agreements. Beginning his career at Amgen, he helped develop and launch Epogen and Neupogen. Mr. Egan also worked for ICOS Corporation where he helped in the discovery and development of Cialis. He was responsible for building and managing the profitable ICOS biologics contract manufacturing business which was later acquired by CMC Biologics. He served as Vice President, Business Development for CMC Biologics where he led US Business Development efforts, and President of Borealis Biotechnology an international business development consulting firm.  Mr. Egan received an MBA from the University of Washington, and a Masters in Biochemistry and Molecular Biology from UC Santa Barbara.

Dr. Thomas Deckwerth has 20 years of industrial experience in the research and development of therapeutics and medical devices. Prior to Pascal, Dr. Deckwerth was Vice President of Cancer Drug Development and Vice President of Product Development at Presage Biosciences where he led optimization and clinical drug product manufacturing projects.  He was one of the first employees at Ikaria, Inc., later acquired by Mallinckrodt Pharmaceuticals. As Senior Director of Biological Chemistry, he led and managed therapeutics and diagnostics projects in the critical care space.  Previously he was Section Head of Cellular Pharmacology at Idun Pharmaceuticals where he worked in collaborations with Novartis on caspase inhibitors for stroke and with Abbott Laboratories in the development of bcl2/bclxL and IAP antagonists for cancer indications until the acquisition of the company by Pfizer.  He received his PhD in neuroscience at Washington University School of Medicine.

 

Dr. Tjoelker has over 25 years of research experience in the biotechnology industry, particularly in drug discovery for immunology and oncology. Prior to joining Pascal, Dr. Tjoelker was at public clinical-stage biotechs including  ICOS, MacroGenics, and Omeros. During his 11-year tenure at ICOS Corporation, he cloned genes for inflammatory mediators which entered late stage clinical trials. As Director of Cancer Discovery at MacroGenics, Dr. Tjoelker and his team discovered 50 new cancer targets for monoclonal antibody therapy. He has also served as Director of Science at Omeros Corp. where his team discovered the first functional monoclonal antibodies against a proinflammatory complement cascade protease. Dr. Tjoelker received his PhD at the University of Michigan.

About Pascal Biosciences Inc. 
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.

 Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443

Media Contact:
Julie Rathbun
Tel: 206-769-9219


DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”